Stifel Maintains Buy on ClearPoint Neuro, Lowers Price Target to $18

Benzinga · 4d ago
Stifel analyst Mathew Blackman maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and lowers the price target from $22 to $18.